Multiple Sclerosis Therapeutic Market Size, Share & Trends Report

Multiple Sclerosis Therapeutic Market (2025 - 2030) Size, Share & Trends Analysis Report By Drug Class (Immunosuppressants, Immunostimulants), By Route Of Administration (Oral, Injectable), By Distribution Channel, By Region, And Segment Forecasts

Market Segmentation

Multiple Sclerosis Therapeutic Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Immunosuppressants
- Immunostimulants
Multiple Sclerosis Therapeutic Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Oral
- Injectable
- Others
Multiple Sclerosis Therapeutic Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
Multiple Sclerosis Therapeutic Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Multiple Sclerosis Therapeutic Market, by Drug Class
    - Immunosuppressants
    - Immunostimulants
  - North America Multiple Sclerosis Therapeutic Market, by Route of Administration
    - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    - Primary Immune Thrombocytopenia (ITP)
    - Generalized Myasthenia Gravis (gMG)
  - North America Multiple Sclerosis Therapeutic Market, by Distribution Channel
    - Oral
    - Injectable
    - Others
  - U.S.
    - U.S. Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - U.S. Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - U.S. Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - Canada
    - Canada Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Canada Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Canada Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - Mexico
    - Mexico Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Mexico Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Mexico Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
- Europe
  - Europe Multiple Sclerosis Therapeutic Market, by Drug Class
    - Immunosuppressants
    - Immunostimulants
  - Europe Multiple Sclerosis Therapeutic Market, by Route of Administration
    - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    - Primary Immune Thrombocytopenia (ITP)
    - Generalized Myasthenia Gravis (gMG)
  - Europe Multiple Sclerosis Therapeutic Market, by Distribution Channel
    - Oral
    - Injectable
    - Others
  - UK
    - UK Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - UK Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - UK Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - Germany
    - Germany Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Germany Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Germany Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - France
    - France Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - France Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - France Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - Italy
    - Italy Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Italy Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Italy Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - Spain
    - Spain Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Spain Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Spain Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - Denmark
    - Denmark Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Denmark Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Denmark Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - Sweden
    - Sweden Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Sweden Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Sweden Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - Norway
    - Norway Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Norway Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Norway Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
- Asia Pacific
  - Asia Pacific Multiple Sclerosis Therapeutic Market, by Drug Class
    - Immunosuppressants
    - Immunostimulants
  - Asia Pacific Multiple Sclerosis Therapeutic Market, by Route of Administration
    - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    - Primary Immune Thrombocytopenia (ITP)
    - Generalized Myasthenia Gravis (gMG)
  - Asia Pacific Multiple Sclerosis Therapeutic Market, by Distribution Channel
    - Oral
    - Injectable
    - Others
  - Japan
    - Japan Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Japan Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Japan Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - China
    - China Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - China Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - China Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - India
    - India Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - India Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - India Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - Australia
    - Australia Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Australia Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Australia Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - South Korea
    - South Korea Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - South Korea Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - South Korea Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - Thailand
    - Thailand Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Thailand Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Thailand Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
- Latin America
  - Latin America Multiple Sclerosis Therapeutic Market, by Drug Class
    - Immunosuppressants
    - Immunostimulants
  - Latin America Multiple Sclerosis Therapeutic Market, by Route of Administration
    - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    - Primary Immune Thrombocytopenia (ITP)
    - Generalized Myasthenia Gravis (gMG)
  - Latin America Multiple Sclerosis Therapeutic Market, by Distribution Channel
    - Oral
    - Injectable
    - Others
  - Brazil
    - Brazil Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Brazil Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Brazil Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - Argentina
    - Argentina Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Argentina Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Argentina Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
- Middle East & Africa
  - Middle East & Africa Multiple Sclerosis Therapeutic Market, by Drug Class
    - Immunosuppressants
    - Immunostimulants
  - Middle East & Africa Multiple Sclerosis Therapeutic Market, by Route of Administration
    - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    - Primary Immune Thrombocytopenia (ITP)
    - Generalized Myasthenia Gravis (gMG)
  - Middle East & Africa Multiple Sclerosis Therapeutic Market, by Distribution Channel
    - Oral
    - Injectable
    - Others
  - South Africa
    - South Africa Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - South Africa Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - South Africa Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - Saudi Arabia
    - Saudi Arabia Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Saudi Arabia Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Saudi Arabia Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - UAE
    - UAE Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - UAE Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - UAE Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others
  - Kuwait
    - Kuwait Multiple Sclerosis Therapeutic Market, by Drug Class
      - Immunosuppressants
      - Immunostimulants
    - Kuwait Multiple Sclerosis Therapeutic Market, by Route of Administration
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Primary Immune Thrombocytopenia (ITP)
      - Generalized Myasthenia Gravis (gMG)
    - Kuwait Multiple Sclerosis Therapeutic Market, by Distribution Channel
      - Oral
      - Injectable
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments